Is LLY a buy in 2026?

Mixed — Framler currently rates it neutral / hold based on the multi-factor Framler engine score of 36/100. Top drivers: Defensive / negative MD&A language flagged; Sector in favour — rotation tailwind; Options skew negative — hedging flow elevated. Framler combines momentum, quality, value, options flow, insider activity and HMM regime detection to score US and international equities daily. This is statistical research, not investment advice.

Is the read supported by multiple factors, or just one?

The page lists how many of the 13 factors point bullish, bearish, or neutral for LLY. Multi-factor alignment indicates stronger conviction; a single-factor signal warrants caution.

Is the uncertainty wide or narrow?

Each ticker shows a 95% Mondrian conformal score-uncertainty range (Vovk-Shafer 2005) — how much the score itself could shift, not a price or return forecast. Narrower ranges indicate the engine's 13 factors agree more strongly; wider ranges reflect a mixed read or factors still calibrating per horizon.

Is the read confirmed by sector and regime?

Sector score, BOCPD regime classification (risk-on / transition / risk-off), and the active confluence pattern all appear on the page. Aligned context tightens conviction; misaligned context widens the interval and softens the verdict.

What would invalidate this read?

Factor flips week-over-week, a regime shift, fresh earnings, or insider sells are the main invalidators. Scores update daily; the 30-day score sparkline above the factor breakdown surfaces trend drift in real time.

Healthcare · NYSE

Calibration 2/4:1d7d30d90d

LLY STOCK · Eli Lilly and Company Neutral

$1,213.91+1.86%

~1-month outlook, not a day-trade. The score updates daily as the data changes — re-check weekly rather than reacting to a single day's move.

AgreementCONFLICTED

Major factor streams disagree — low conviction.

90% interval: [5–82]Top driver: NLP Tone

PATTERN HISTORY · 14Dhit rate 65.4%mean ret +6.50%n=136Measured across every ticker that fired this setup — not this stock's own history.

Below-average factor outlook for this regime🔒 Sign in for number

Why LLY scores 36

Defensive / negative MD&A language flagged
Sector in favour — rotation tailwind
Options skew negative — hedging flow elevated

Full report — sign in to unlock

🧬 Phase 3 / FDA catalyst

LLY has an active Phase 3 clinical trial — NCT06948435. Framler models the failure probability for LLY from ClinicalTrials.gov data — the figure is shown after you sign in.

🧬 Biotech intelligence

Bayesian Phase-3 trial failure probability vs the disease base rate, an estimated FDA decision window, patent-cliff timing, and comparable historical trials — the biotech layer for LLY.

🔒 Sign up to unlock →

🔒 Forward-Return Projection

Expected returns over 1 / 7 / 30 / 90 days with 90% confidence intervals, regime amplifier, pattern multiplier, copula tail-dependence — composed into one Bayesian distribution.

🔒 Full Factor Breakdown

Per-factor 0-100 scores across quality, value, momentum, PEAD, accruals, insider flow, NLP tone, options flow, short interest, sector momentum, factor interaction — plus the score waterfall.

🔒 Confluence Patterns

Active multi-factor patterns (QUALITY COMPOUNDER, VALUE TRAP, SHORT SQUEEZE, OVEREXTENDED, etc.) with academic basis and pattern delta against the raw composite.

🔒 Plain-English Explanation & Scenarios

Plain-English read of what the engine sees on this ticker today + what-if scenarios (price ±N%, regime flip, shock) replayed through the deterministic engine. No AI in the scoring path.

Unlock the full LLY report

Free during early access · no credit card · 1,000+ stocks tracked daily